Brain tumor treatment faces a critical age gap that could be leaving younger patients with suboptimal care plans. While meningiomas represent the second most common brain tumor in adolescents and young adults, the molecular tools guiding treatment decisions have been developed almost exclusively using adult patient data—a oversight with potentially serious clinical consequences.
Analysis of 1,568 meningioma cases across age groups revealed that pediatric and young adult tumors exhibit fundamentally different molecular signatures compared to adult cases. Despite similar appearance under the microscope, younger patients showed significantly fewer aggressive molecular subtypes and lower rates of specific chromosomal deletions, particularly losses of chromosomal arms 1p, 6q, and 14q. Most strikingly, adult-trained recurrence prediction models performed poorly in younger patients, achieving only 57% accuracy compared to the 79% accuracy possible with age-appropriate tools.
This molecular divergence suggests that meningiomas in younger patients may represent biologically distinct entities rather than simply earlier versions of adult tumors. The finding challenges the common practice of extrapolating adult treatment protocols to pediatric and young adult populations. Age-specific molecular profiling could revolutionize treatment selection, particularly given that 1p chromosomal loss retained prognostic value within the younger cohort, indicating that some established biomarkers remain relevant when properly contextualized. The research underscores a broader need for precision medicine approaches that account for developmental biology rather than assuming uniform disease mechanisms across lifespans.